Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL8326 in advanced small cell lung cancer
ISRCTN79004846Phase 3Recruiting
- Sponsor
- Advenchen Laboratories
- Start
- Nov 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing AL8326 with Placebo (2 arms). Primary endpoint: Overall survival. Started Nov 2024; status: recruiting.
02
Drugs
AL8326
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ISRCTN79004846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN79004846.